Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A LeWitt

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
Neurology|January 1, 1992
Clinical studies with and pharmacokinetic considerations of sustained-release levodopaP A LeWitt
Neurology|June 17, 1999
Micrographia after thalamo-mesencephalic infarctionP A LeWitt
Pharmacotherapy|January 21, 2000
New drugs for the treatment of Parkinson's diseaseP A LeWitt
Advances in Neurology|January 1, 1993
Assessment of the dopaminergic lesion in Parkinson's disease by CSF markersP A LeWitt
Journal of Neural Transmission. Supplementum|April 24, 2007
Neuroprotection for Parkinson's diseaseP A LeWitt
Pharmacotherapy|January 21, 2000
The challenge of managing mild Parkinson's diseaseP A LeWitt
European Neurology|January 1, 1993
Neuroprotection by anti-oxidant strategies in Parkinson's diseaseP A LeWitt
The New England Journal of Medicine|January 10, 1980
The neurotoxicity of the rat poison vacor. A clinical study of 12 casesP A LeWitt
Clinical Neuropharmacology|January 1, 1986
New perspectives in the treatment of Parkinson's diseaseP A LeWitt
Movement Disorders : Official Journal of the Movement Disorder Society|August 1, 1998
Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's diseaseP A LeWitt
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Neurology|January 1, 1992
Clinical studies with and pharmacokinetic considerations of sustained-release levodopaP A LeWitt
Neurology|June 17, 1999
Micrographia after thalamo-mesencephalic infarctionP A LeWitt
Pharmacotherapy|January 21, 2000
New drugs for the treatment of Parkinson's diseaseP A LeWitt
Advances in Neurology|January 1, 1993
Assessment of the dopaminergic lesion in Parkinson's disease by CSF markersP A LeWitt
Journal of Neural Transmission. Supplementum|April 24, 2007
Neuroprotection for Parkinson's diseaseP A LeWitt
Pharmacotherapy|January 21, 2000
The challenge of managing mild Parkinson's diseaseP A LeWitt
European Neurology|January 1, 1993
Neuroprotection by anti-oxidant strategies in Parkinson's diseaseP A LeWitt
The New England Journal of Medicine|January 10, 1980
The neurotoxicity of the rat poison vacor. A clinical study of 12 casesP A LeWitt
Clinical Neuropharmacology|January 1, 1986
New perspectives in the treatment of Parkinson's diseaseP A LeWitt
Movement Disorders : Official Journal of the Movement Disorder Society|August 1, 1998
Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's diseaseP A LeWitt
Pageof 11